Navigation Links
Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
Date:9/25/2008

EMERYVILLE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that previously found excess symptomatic intracranial hemorrhage in an earlier European trial of ancrod (now Viprinex(TM)) for the treatment of acute ischemic stroke may be minimized with avoidance of prolonged low levels of fibrinogen and use of common blood pressure entry criteria.

The data, presented today at the 6th World Stroke Conference in Vienna, Austria, are from a retrospective analysis led by NTI scientists of two previous Phase 3 clinical trials, known as STAT and ESTAT, which involved more than 1700 patients and were conducted before NTI acquired the rights to ancrod. The STAT trial in the United States showed ancrod-treated patients had a better outcome than placebo-treated patients, while the European ESTAT trial showed an ancrod treatment outcome similar to placebo, but a higher rate of symptomatic intracranial hemorrhages. When the drug safety information from the trials were compared, it was noted that patients treated with ancrod in ESTAT who had symptomatic intracranial hemorrhages were more likely to have had prolonged low fibrinogen blood levels, to have received higher doses of ancrod and to have had higher blood pressures at trial entry.

"The conclusions of this analysis provided NTI with the information needed to revise the dosing regimen to avoid prolonged low fibrinogen levels and launch new Phase 3 clinical trials using common blood pressure patient-entry criteria," says Gregory del Zoppo, M.D. of the University of Washington, chairman of the current ancrod clinical trials' steering committee, and a coauthor of the retrospective analysis.

"Earlier Viprinex trials
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) ... to successfully open a patient,s blocked artery with a ... drill" to painlessly remove the plaque buildup which causes ... – conducted Wednesday by CVI Director of Endovascular Medicine ...
... HistoRx, the leader in quantitative immunohistochemistry, advances ... recent issuance of US patents covering key features ... results.  The U.S. Patent and Trademark Office has ... for standardization of digital microscopy instruments, methods required ...
Cached Medicine Technology:DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage 2DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage 3HistoRx Earns Two Additional Patents on Standardization of Results from Digital Pathology Instruments 2HistoRx Earns Two Additional Patents on Standardization of Results from Digital Pathology Instruments 3
(Date:7/13/2014)... MillionaireCasket.com is a professional supplier of funeral products. According to ... well in the global market. Recently, the company has announced ... a special offer for all the newly released items. ... caskets are made with superb materials. As is commonly noted, ... respect to the departed saint. MillionaireCasket.com is always here to ...
(Date:7/13/2014)... 13, 2014 Intraocular Lens (IOL) Market: ... 2013 - 2019 , Intraocular lens (IOL) is inserted ... or cataracts. The lenses are inserted inside the eye, ... intraocular lens replaces the focusing power of natural lens. ... lens to deliver the light focusing function which was ...
(Date:7/13/2014)... Victorian Hotel has recently announced that ... of bikes for its "Cycle the City" program, which ... tour the area using a rental bicycle, available for ... to call Vancouver home, as it is a city ... picturesque journeys through the countryside. Vancouver hotel rooms often ...
(Date:7/13/2014)... additives are chemicals, which are added to various fuels ... on, in order to enhance their performance. Fuel additives ... by fuels and improving the combustion properties of fuels. ... scale in the long run, but, in the short ... products. , The various fuel additive types include deposit ...
(Date:7/13/2014)... The Pearland, Texas location of The Little Gym, a ... to 12 years of age that offers everything from gymnastics, ... Summer Camps, is now under new ownership. , Kevin Berry ... spending over six years at The Little Gym of Bellaire ... Berry has over ten years of experience working with children, ...
Breaking Medicine News(10 mins):Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2
... ... received its first batch of Spirits Bay Manuka Honey tested for activity using ... is a registered trademark of the University of Waikato, home of the Honey ... of manuka honey. Produced by a Maori-owned apiary in a remote area of ...
... ... employee wellness programs , ... GA (Vocus) April 7, 2010 -- R. Shane Jackson, president of LocumTenens.com and ... for Health Transformation,s (CHT) first member meeting of 2010, which took place on March 25 ...
... poor people have higher death rates than rich within first decade ... more likely to die within five to 10 years after heart ... 15,156 white men, 6,932 white women, 678 black men and 564 ... and 2005 and found that the poorest patients were 19 to ...
... , ... today released version 4.3 of Replay, the award-winning, next generation backup and disaster recovery ... ... 4.3 of Replay, the award-winning, next generation backup and disaster recovery software solution. ...
... a means of heterosexual interaction on university campuses, more women ... women rate hooking up above dating. Both genders however perceive ... Bradshaw from James Madison University in Virginia, US, and colleagues ... hook up or to date, as well as the perceived ...
... vaccine were at higher risk, study found, but that ... (HealthDay News) The traditional seasonal flu vaccine may ... swine flu, according to the results of four new ... researchers used an ongoing sentinel monitoring system to assess ...
Cached Medicine News:Health News:Koru Naturals Becomes the First U.S. Company to Import Molan Gold Standard Manuka Honey 2Health News:R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting 2Health News:R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting 3Health News:Poor More Likely to Die Following Heart Surgery 2Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 2Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 3Health News:Hooking up or dating: Who benefits? 2Health News:Did 'Regular' Flu Shot Up Risks for H1N1 Flu? 2
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
Freedom Clear® SS Sport Sheath is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath designed for everyday wear. Its brief sheath minimizes roll at the base of the p...
The UltraFlex® all silicone self-adhering male external catheter is 100% latex-free and eliminates the risk of latex-related skin irritations. This breathable catheter promotes healthy skin and i...
... all-silicone Foley catheters eliminate patient exposure ... catheter designs. As an inert, toxin-free ... a safe, dependable Foley catheter. Unlike ... catheters will not leach chemicals or ...
Medicine Products: